Stockscreener 앱 받기
2.65
0.38%
-0.01
Sonoma Pharmaceuticals Inc 주식(SNOA)의 최신 뉴스
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 - Marketscreener.com
Sonoma Pharmaceuticals (SNOA) to Release Quarterly Earnings on Thursday - Defense World
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results - ACCESS Newswire
Sonoma Pharmaceuticals secures new supply agreement - MSN
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Sonoma Pharmaceuticals secures new supply agreement By Investing.com - Investing.com South Africa
Dental Market Future Business Opportunities 2025-2032 | - openPR
Hypertrophic And Keloid Scar Treatment Global Market Expected To Ascend to $12.51 Billion By 2029 - WhaTech
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Industry Decline - GuruFocus.com
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - ACCESS Newswire
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany - ACCESS Newswire
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea - ACCESS Newswire
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma County Sheriff arrests 3, seizes guns and fentanyl in drug bust - CBS San Francisco
Global Hypertrophic And Keloid Scar Treatment Market: Key - openPR
Animal Wound Care Market: Exploring Projected Size, CAGR, Key Players & Trends - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Scar Treatment Market to Surge with 10.9% CAGR, Global Revenue to Exceed US$ 8.24 Billion by 2034 - EIN News
Redhill Biopharma (NASDAQ:RDHL) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Dental Market Set to Witness Significant Growth by 2025-2032: Sonoma Pharmaceuticals, Inc., Henry Schein, Inc, - EIN News
Scar Treatment Market Analysis: Key Drivers and Growth Projections Through 2027 - openPR
Sonoma Pharmaceuticals announces executive equity grants By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals announces executive equity grants - Investing.com India
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Urinary Catheters Market Set to Witness Significant Growth by 2024-2031 | B. Braun SE, Coloplast Corp, BD, Cathetrix - openPR
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
2 Sonoma County men busted for alleged drug dealing in Marin - KRON4
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com Canada
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Bags of cocaine, gun found in Santa Rosa drug bust - KRON4
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
0.25%
0.51%
자본화:
|
볼륨(24시간):